Growth Metrics

Emergent BioSolutions (EBS) Non-Current Assets: 2010-2025

Historic Non-Current Assets for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $674.1 million.

  • Emergent BioSolutions' Non-Current Assets fell 17.43% to $674.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $674.1 million, marking a year-over-year decrease of 17.43%. This contributed to the annual value of $791.0 million for FY2024, which is 30.84% down from last year.
  • Per Emergent BioSolutions' latest filing, its Non-Current Assets stood at $674.1 million for Q3 2025, which was down 3.37% from $697.6 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Non-Current Assets high stood at $2.0 billion for Q4 2022, and its period low was $674.1 million during Q3 2025.
  • Its 3-year average for Non-Current Assets is $1.0 billion, with a median of $859.0 million in 2024.
  • Per our database at Business Quant, Emergent BioSolutions' Non-Current Assets grew by 15.88% in 2022 and then crashed by 41.53% in 2023.
  • Emergent BioSolutions' Non-Current Assets (MRQ) stood at $1.7 billion in 2021, then rose by 15.88% to $2.0 billion in 2022, then tumbled by 41.53% to $1.1 billion in 2023, then crashed by 30.84% to $791.0 million in 2024, then decreased by 14.78% to $674.1 million in 2025.
  • Its Non-Current Assets was $674.1 million in Q3 2025, compared to $697.6 million in Q2 2025 and $719.3 million in Q1 2025.